Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.

Geoffrey J. Lindeman,Aditya Bardia,Rebecca Bowen,Aulde Flechais,Guiyuan Lei,Alexandra Hogea,Mehrdad Mobasher,Saeed Rafii

Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.

2019

Geoffrey J. Lindeman
Aditya Bardia
Rebecca Bowen
Aulde Flechais
Guiyuan Lei
Alexandra Hogea
Mehrdad Mobasher
Saeed Rafii

TPS1108Background: CDK4/6 inhibitors (CDK4/6is) administered with endocrine therapy have demonstrated improvements in progression-free survival (PFS) for estrogen receptor (ER)+ advanced breast can...

Keywords:

Estrogen receptor
Fulvestrant
Pathology
Oncology
Metastatic breast cancer
Venetoclax
Medicine
Internal medicine
locally advanced
endocrine therapy
advanced breast

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations